Eng C, Brody L C, Wagner T M, Devilee P, Vijg J, Szabo C, Tavtigian S V, Nathanson K L, Ostrander E, Frank T S
Clinical Cancer Genetics and Human Cancer Genetics Programs, Comprehensive Cancer Center, and Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
J Med Genet. 2001 Dec;38(12):824-33. doi: 10.1136/jmg.38.12.824.
While sequence analysis is considered by many to be the most sensitive method of detecting unknown mutations in large genes such as BRCA1, most published estimates of the prevalence of mutations in this gene have been derived from studies that have used other methods of gene analysis. In order to determine the relative sensitivity of techniques that are widely used in research on BRCA1, a set of blinded samples containing 58 distinct mutations were analysed by four separate laboratories. Each used one of the following methods: single strand conformational polymorphism analysis (SSCP), conformation sensitive gel electrophoresis (CSGE), two dimensional gene scanning (TDGS), and denaturing high performance liquid chromatography (DHPLC). Only the laboratory using DHPLC correctly identified each of the mutations. The laboratory using TDGS correctly identified 91% of the mutations but produced three apparent false positive results. The laboratories using SSCP and CSGE detected abnormal migration for 72% and 76% of the mutations, respectively, but subsequently confirmed and reported only 65% and 60% of mutations, respectively. False negatives therefore resulted not only from failure of the techniques to distinguish wild type from mutant, but also from failure to confirm the mutation by sequence analysis as well as from human errors leading to misreporting of results. These findings characterise sources of error in commonly used methods of mutation detection that should be addressed by laboratories using these methods. Based upon sources of error identified in this comparison, it is likely that mutations in BRCA1 and BRCA2 are more prevalent than some studies have previously reported. The findings of this comparison provide a basis for interpreting studies of mutations in susceptibility genes across many inherited cancer syndromes.
虽然许多人认为序列分析是检测BRCA1等大基因中未知突变最灵敏的方法,但该基因中突变发生率的大多数已发表估计值都来自使用其他基因分析方法的研究。为了确定在BRCA1研究中广泛使用的技术的相对灵敏度,四个独立实验室对一组包含58种不同突变的盲样进行了分析。每个实验室使用以下方法之一:单链构象多态性分析(SSCP)、构象敏感凝胶电泳(CSGE)、二维基因扫描(TDGS)和变性高效液相色谱(DHPLC)。只有使用DHPLC的实验室正确识别了每一种突变。使用TDGS的实验室正确识别了91%的突变,但产生了三个明显的假阳性结果。使用SSCP和CSGE的实验室分别检测到72%和76%的突变出现异常迁移,但随后分别仅确认并报告了65%和60%的突变。因此,假阴性不仅源于技术未能区分野生型和突变型,还源于未能通过序列分析确认突变以及人为错误导致结果误报。这些发现揭示了常用突变检测方法中的误差来源,使用这些方法的实验室应予以解决。基于本次比较中确定的误差来源,BRCA1和BRCA2中的突变可能比一些研究先前报道的更为普遍。本次比较的结果为解释许多遗传性癌症综合征中易感基因的突变研究提供了依据。